Clinical Professor of Neurology at LSU Health Sciences Center New Orleans.

Home / gynecology / Clinical Professor of Neurology at LSU Health Sciences Center New Orleans.

Clinical Professor of Neurology at LSU Health Sciences Center New Orleans.

Child Neurology Society honors LSUHSC professor with 2012 Hower Award The young child Neurology Society presented Ann Henderson Tilton, MD, Clinical Professor of Neurology at LSU Health Sciences Center New Orleans, in November with the 2012 Hower Award at the 41st Annual CNS Meeting. The award, directed at one young child neurologist each complete year, honors an outstanding teacher and scholar whose contributions to the specialty have already been recognized at national and international levels http://cialissverige.org/lakemedel-online.html . Dr. Tilton is normally a Professor of Neurology and Pediatrics and Section Seat of Kid Neurology at Louisiana State Health Science Middle in New Orleans, Louisiana.

ed piller

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML ChemGenex Pharmaceuticals Limited announced today it offers agreed with the U.S. Based on the debate with the FDA, ChemGenex intends to combine data from its two pivotal research, Study 202 and Study 203, and send a New Drug Program for OMAPRO for all those patients with CML who have failed prior treatment with two or more currently accepted tyrosine kinase inhibitors . The proposed indication of the new NDA will be for the treating CML patients who have failed several TKIs, no matter their mutation status. Related StoriesProtein-coding gene identified as tumor suppressor for severe myeloid leukemiaPenn study forms basis for new treatment techniques for Sezary syndromeYK-4-279 compound works against some types of leukemia: Study The FDA’s agreement that a combined data established could serve as the foundation of an NDA in a third-range placing provides us with a pathway to an extended indication for OMAPRO to take care of CML patients who are resistant to at least two TKIs, stated Adam Craig, MD, Chief Medical Officer of ChemGenex.